Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Clinical trial NCT02315326 · COMPLETED

Trial details

NCT number: NCT02315326
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Start date: 2014-12-08
Primary completion: 2026-01-28
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.